MOTS-C vs Retatrutide for energy
Short answer: For energy, more users report improvement with MOTS-C — 83% of 78 reports, versus 69% of 75 for Retatrutide.
MOTS-C has 0 meta-analyses and 4 randomized trials on PubMed; Retatrutide has 22 and 6.
Based on 213 reports about MOTS-C and 460 about Retatrutide. Not medical advice.
| MOTS-C Peptide | Retatrutide Peptide | |
|---|---|---|
| Users say it helped | 49%helped100 reports · high confidence | 76%helped327 reports · high confidence |
| Verdict | Mixed | Mostly positive |
| Research | CResearch: Limited | BResearch: Moderate |
| Meta-analyses / RCTs | 0 / 4 | 22 / 6 |
| Mainly used for | ||
| Weight loss % reporting improvement | 86% (14) | 92% (228) |
| Energy % reporting improvement | 83% (78) | 69% (75) |
| Appetite % reporting improvement | — | 73% (86) |
| Performance % reporting improvement | 85% (34) | 82% (33) |
| Mood % reporting improvement | 100% (5) | 66% (32) |
| Common side effects | insomnia, injection site, dizziness, jitteriness | nausea, fatigue, stomach issues, insomnia |
| Typical dose reported | Not listed | Not listed |
“Taking these makes me feel wildly energetic all day—zero afternoon slumps, and my endurance during cardio feels bottomless.”
This systematic review identifies the state and mechanism of action of emerging pharmacotherapies undergoing or having completed phase 2 and phase 3 clinical trials. The information provided herein furthers the understanding of obesity management, implying direct clinical implications and stimulating research initiatives.
Pharmacol Rev, 2025 ↗“Drastically reduced appetite: At 5mg, I experienced near-total suppression of hunger and cravings. Steady, effortless fat loss: I didn't have to track macros obsessively or do extreme cardio.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate